The summer witnessed another episode in the ongoing ‘rationing’ saga about NHS provision of the Alzheimer drugs rivastigmine, donepezil, and galantamine. The High Court upheld the substance of NICE’s guidance, which means that these drugs continue to be recommended only for people with ‘moderate’ Alzheimer’s.